SR-33805 is a calcium channel antagonist potentially for the treatment of atherosclerosis and heart failure. SR-33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes. A SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR-33805. References: Howlett SE. Searching for the ideal inotropic agent to rescue a failing heart. Cardiovasc Res. 2011 Aug 1;91(3):371-2. doi: 10.1093/cvr/cvr164. Epub 2011 Jun 7. PubMed PMID: 21652598.

纯度：≥98%

CAS：121346-32-5